Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00007239

Trial Description

start of 1:1-Block title

Title

Phase III Study on Alternative Dosing Regimens in the Pharmacotherapy of Mild to Moderate Insomnia

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

ALPHASOM

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The purpose of this study is to evaluate whether drug efficiency of zolpidem and
amitriptyline can be conditioned according to learning theory in patients with primary
insomnia.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Previous research has shown that repeated drug treatments can be regarded as conditioning
processes. Sleep disorders are especially of interest to be investigated under the
perspective of conditioning with drugs, since sleep quality can be defined both in terms of
subjective ratings (self-rated sleep quality parameters) and objective measures (via
polysomnographic assessment PSG; e.g., total sleep time, sleep onset, sleep architecture).
By using two different drugs (zolpidem, amitriptyline) that modulate sleep differentially,
the investigators intend to implement a conditioning paradigm in sleep disorders
dissociating conditioning effects on subjective and objective sleep parameters. Both drugs
should affect objective and subjective sleep parameters positively, while only amitriptyline
should modulate the objectively assessed sleep architecture by REM-suppression (latency of
REM-sleep onset, percentage of REM-sleep).Patients with mild to moderate insomnia will
undergo a classical conditioning paradigm with one of two study medications: amitriptyline
or zolpidem. After an acquisition period and a wash-out period, conditioned sleep changes
are assessed in an evocation trial. During a second treatment phase of 7 days, patients
receive different doses of amitriptyline (between 0mg and 50mg per night) or zolpidem
(between 0mg and 5mg per night) to evaluate alternative dosing regimens in the
pharmacotherapy of mild to moderate Insomnia.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00007239
  •   2015/05/06
  •   2014/04/24
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2013-003229-27 
  •   NCT02139098  (ClinicalTrials.gov)
  •   FOR1328-SP8  (Philipps University Marburg Medical Center)
  •   2013-003229-27 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Insomnia
  •   F51.0 -  Nonorganic insomnia
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Amitriptyline
  •   Drug: Zolpidem
  •   Drug: Amitriptyline
  •   Drug: Placebo
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, caregiver, investigator/therapist, assessor
  •   Placebo, Active control
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Objective Total Sleep Time; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- Objective Sleep Onset Latency; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- Self-reported Total Sleep Time; time frame: Change from baseline to day 10 after first medication intake; assessed by sleep diary
- Self-Reported Sleep Onset Latency; time frame: Change from baseline to day 10 after first medication intake; assessed by sleep diary

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Percentage of REM sleep; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- REM onset latency; time frame: Change from baseline to day 10 after first medication intake; assessed by polysomnography
- Objective Sleep Efficiency; time frame: Change from baseline to day 17 after first medication intake; assessed by actigraphy
- Objective Total Sleep Time; time frame: Change from baseline to day 17 after first medication intake; assessed by actigraphy
- Self-Reported Total Sleep Time; time frame: Change from baseline to day 18 after first medication intake; assessed by sleep diary
- Self-reported Sleep Onset Latency (min); time frame: Change from baseline to day 18 after first medication intake; assessed by sleep diary
- Self-reported Sleep Onset Latency (evaluation); time frame: Change from baseline to day 18 after first medication intake; assessed by sleep diary

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2014/05/31
  •   150
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   69   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. age between 18 years to 69 years

2. fluent in German language

3. provide written informed consent

4. ability to understand the explanations and instructions given by the study physician
and the investigator

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Sleep disorders caused by medical factors (e.g. sleep apnea, restless legs syndrome,
narcolepsy, substance-induced insomnia)

2. Contraindications to study medication intake according to the information sheet for
health professionals (Summary of medicinal Product Characteristics, SmPC;
Fachinformation in Germany) assessed by physical examination (including ECG) and
medical history

- allergies to amitriptyline hydrochloride or any of its ingredients

- allergies to zolpidem or any of its ingredients

- acute intoxication with alcohol, analgetics, hypnotics or any other psychotropic
drug

- urinary retention

- delirium

- untreated closed-angle glaucoma

- prostatic hyperplasia

- pyloric stenosis

- paralytic ilius

- suicidal thoughts

- liver/ kidney/ pulmonary insufficiency

- myasthenia gravis

- hypokalemia

- bradycardia

- coronary heart disease, cardiac arrhythmias, long QT syndrome or other
clinically relevant cardiac disorders

- increased risk of seizures/ history of seizures

- substance dependence syndrome/ history of substance dependence syndrome

3. Allergies to ingredients of placebo or novel-tasting drink (CS)

4. currently pregnant (verified by urine pregnancy test) or lactating

5. patients scoring ≥12 on the Epworth Sleepiness Scale

6. patients scoring below 8 or above 21 on the Insomnia Severity Index

7. patients suffering from a mental disorder as verified by the SCID (major depression;
psychosis; brain injury; substance abuse or dependency syndrome during the last 6
months before V1)

8. nicotine consumption > 10 cigarettes/day

9. unwillingness to refrain from alcohol consumption throughout the study

10. Concomitant medication interfering with study medication intake due to potential
interactions (all psychotropic medication including analgetics and muscle relaxants,
hypericum derivatives; antihypertensives; anti-arrhythmic agents; antibiotics;
cisaprid; anti-malaria drugs; diuretics; imidazole antifungals; cumarin derivatives;
antihistaminics; calcium channel blockers; medications that enlarge the QT interval
or may lead to hypokalemia)

11. change in concomitant medication regime during the last 2 weeks prior to visit 1 or
after randomization

12. intake of psychotropic medication during the last 3 months

13. participation in any other clinical trial 3 months prior to visit 1

14. women of childbearing age not using 2 highly effective contraceptive methods

15. employee of the Sponsor or the principal investigator

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Philipps University Marburg Medical Center
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Department of Pneumology, Medical School, Philipps University Marburg
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address other
    • Institute of Laboratory Medicine, Pathobiochemistry and Molecular Diagnostics, Philipps University Marburg
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address other
    • University Medical Center, Johannes Gutenberg University Mainz
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address other
    • Philipps University Marburg Coordination Centre for Clinical Trials
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Clinical Psychology and Psychotherapy, Department of Psychology, Philipps University Marburg
    • Winfried Rief, Prof. Dr. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Bettina K Doering, Dr. 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   1
  •   2014/11/05
* This entry means the parameter is not applicable or has not been set.